CYCN Insider Trading Activity and SEC Form 4 Filings
CYCN insider trading summary
No open-market insider purchases or sales of Cyclerion Therapeutics, Inc. (CYCN) have been reported on SEC Form 4 in the past 12 months.
Latest CYCN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 21, 2024 | Slate Path Capital LP | 10% Owner | Sell | $555K (357,880 @ $1.55) |
| Nov 21, 2024 | David Gerald Greenspan | 10% Owner | Sell | $555K (357,880 @ $1.55) |
| Aug 9, 2023 | Terrance McGuire | Director | Sell | $27 (8 @ $3.40) |
| Jun 3, 2021 | Peter M Hecht | Chief Executive Officer | Buy | $2.7M (823,170 @ $3.28) |
| Jun 3, 2021 | Terrance McGuire | Director | Buy | $290K (92,831 @ $3.12) |
| Jun 3, 2021 | David Gerald Greenspan | 10% Owner | Buy | $3.0M (961,538 @ $3.12) |
| Jun 3, 2021 | Slate Path Capital LP | 10% Owner | Buy | $3.0M (961,538 @ $3.12) |
| Jun 3, 2021 | Terrance McGuire | Director | Buy | $10K (3,322 @ $3.12) |
| May 6, 2021 | Peter M Hecht | Chief Executive Officer | Buy | $734K (302,000 @ $2.43) |
| May 5, 2021 | Peter M Hecht | Chief Executive Officer | Buy | $1.0M (398,001 @ $2.53) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.